NCT07028645

Brief Summary

This study will evaluate the uroflowmetry parameters of patients which were treated for enuresis.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 20, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 11, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 19, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

June 24, 2025

Status Verified

June 1, 2025

Enrollment Period

2 years

First QC Date

June 11, 2025

Last Update Submit

June 18, 2025

Conditions

Keywords

UroflowmetryEnuresis

Outcome Measures

Primary Outcomes (1)

  • Number of days without bedwetting

    Achievement of bedwetting in one or less night of a month

    1 month

Study Arms (3)

Desmopressin 120mcg

Patients treated with desmopressin 120 mcg

Drug: desmopressin melt form 120 μg

Desmopressin 240 mcg

Patients treated with desmopressin 240mcg

Drug: Desmopressin lyophilisate (Melt)

Desmopressin 240 mcg + anticholinergic

Patients treated with desmopressin 240mcg + anticholinergic agent

Drug: Propiverine tablet

Interventions

Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.

Desmopressin 120mcg

Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.

Desmopressin 240 mcg

Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg

Desmopressin 240 mcg + anticholinergic

Eligibility Criteria

Age5 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Patients who were treated for enuresis in pediatric urology clinic of Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital

You may qualify if:

  • Presence of enuresis nocturna
  • Patients who have uroflowmetry test

You may not qualify if:

  • Presence of lower urinary tract symptoms
  • Presence of anatomical or neurological problems
  • Patients with missing data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, Kadikoy, 34000, Turkey (Türkiye)

Location

Related Publications (1)

  • Kang BJ, Chung JM, Lee SD. Evaluation of Functional Bladder Capacity in Children with Nocturnal Enuresis According to Type and Treatment Outcome. Res Rep Urol. 2020 Sep 15;12:383-389. doi: 10.2147/RRU.S267417. eCollection 2020.

    PMID: 32984086BACKGROUND

MeSH Terms

Conditions

Nocturnal EnuresisEnuresis

Interventions

Freezingpropiverine

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesBehavioral SymptomsBehaviorElimination DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Phase TransitionPhysical PhenomenaCold TemperatureTemperatureThermodynamicsChemical Phenomena

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Medical doctor

Study Record Dates

First Submitted

June 11, 2025

First Posted

June 19, 2025

Study Start

August 20, 2022

Primary Completion

September 1, 2024

Study Completion

December 30, 2025

Last Updated

June 24, 2025

Record last verified: 2025-06

Locations